Recently stock market analysts have updated their consensus ratings on shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

05/06/2016 – Atara Biotherapeutics, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 22 price target on the stock.

12/29/2015 – Atara Biotherapeutics, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 47 price target on the stock.

12/15/2015 – Atara Biotherapeutics, Inc. had its “buy” rating reiterated by analysts at William Blair.

12/15/2015 – Atara Biotherapeutics, Inc. had its “market outperform” rating reiterated by analysts at JMP Securities. They now have a USD 40 price target on the stock.

12/15/2015 – Atara Biotherapeutics, Inc. was downgraded to “sell” by analysts at Citigroup. They now have a USD 16 price target on the stock.

11/18/2015 – Goldman Sachs began new coverage on Atara Biotherapeutics, Inc. giving the company a “neutral” rating.

05/13/2015 – Atara Biotherapeutics, Inc. was downgraded to “sell” by analysts at Zacks.

Atara Biotherapeutics, Inc. has a 50 day moving average of 19.12 and a 200 day moving average of 22.68. The stock’s market capitalization is 433.47M, it has a 52-week low of 13.31 and a 52-week high of 65.56.

The share price of the company (NASDAQ:ATRA) was down -0.98% during the last trading session, with a high of 15.54 and the volume of Atara Biotherapeutics, Inc. shares traded was 261769.

View other investors thoughts on Atara Biotherapeutics, Inc. on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.